The Subscription Period for the Warrants of Series TO1 in Stayble Therapeutics AB begins Today October 17, 2020
Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right to subscribe one new share in the Company to an exercise price of SEK 12,30 per share.
Summarised terms for the warrants of series TO1
Subscription period for subscription of shares: November 17, 2020 – December 1, 2020.
Issue size: 2,580,000 warrants of series TO1, which entitles to subscription of 2,850,000 shares. If all the warrants are exercised, The Company will receive approximately SEK 35 million before issue cost.
Exercise price: SEK 12.30 per share.
Last day for trading warrants of series TO1: November 25, 2020.
Note that the warrants that are not sold at the latest November 25, 2020, or exercised at the latest December 1, 2020, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.
Ownership letters to warrant holders of series TO1 are attached to this press release and are also available on the Company's website, www.staybletherapeutics.com, and Mangold Fondkommissions AB’s webpage, www.mangold.se. The terms and condition for the warrants were included as part of the prospectus published in connection with the listing published on January 31, 2020. The prospectus with terms and conditions for the warrants is also available at the websites above.
How warrants are exercised
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office. The application form including instructions for payment will be available at the Company’s website, www.staybletherapeutics.com, and on Mangold Fondkommissions AB’s website, www.mangold.se.
Mangold Fondkommission AB is the financial adviser and the Lawfirm Schjødt AS is the leagel adviser to Stayble regarding the warrents.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
+46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail firstname.lastname@example.org